Access the full text.
Sign up today, get DeepDyve free for 14 days.
T. Choueiri, D. Heng, J. Lee, M. Cancel, R. Verheijen, A. Mellemgaard, L. Ottesen, M. Frigault, Anne L’hernault, Z. Szíjgyártó, S. Signoretti, L. Albiges (2020)
Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell CarcinomaJAMA Oncology, 6
D. Miles, S. Lacy, D. Wada, S. Milwee, Y. Yaron, L. Nguyen (2017)
Assessment of cabozantinib treatment on QT interval in a phase 3 study in medullary thyroid cancer: evaluation of indirect QT effects mediated through treatment-induced changes in serum electrolytesCancer Chemotherapy and Pharmacology, 80
S. Kim, Sujin Lee, Minhwa Park, S. Park, Joon-Oh Park, Ho Lim, Y. Park, W. Kang, E. Gangolli, Hyeongchan Shin, Kyoung-Mee Kim, S. Hollingsworth, P. Mortimer, Jeeyun Lee (2019)
Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I TrialTranslational Oncology, 12
O. Hamill, A. Marty, E. Neher, B. Sakmann, F. Sigworth (1981)
Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patchesPflügers Archiv, 391
T. Kim, Philipp Coutre, Michaela Schwarz, Peggy Grille, Michal Levitin, Suzanne Fateh-Moghadam, F. Giles, B. Dörken, W. Haverkamp, C. Köhncke (2012)
Clinical cardiac safety profile of nilotinibHaematologica, 97
Yi Gu, Y. Sai, Jian Wang, Meijing Yu, Guanglin Wang, Li Zhang, Hong-Can Ren, S. Fan, Yongxin Ren, Weiguo Qing, W. Su (2019)
Preclinical pharmacokinetics, disposition, and translational pharmacokinetic/pharmacodynamic modeling of savolitinib, a novel selective cMet inhibitor.European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 136
C. Porte (2008)
Inhibitory quotient in HIV pharmacologyRetrovirology, 7
J. Kloth, Anna Pagani, M. Verboom, A. Malovini, C. Napolitano, W. Kruit, S. Sleijfer, N. Steeghs, A. Zambelli, R. Mathijssen (2015)
Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitorsBritish Journal of Cancer, 112
P. Gavine, Yongxin Ren, Lu Han, Jing Lv, S. Fan, Wei Zhang, Wen Xu, Yuanjie Liu, Tianwei Zhang, Haihua Fu, Yongjuan Yu, Huiying Wang, Shirlian Xu, Fengmin Zhou, Xinying Su, Xiaolu Yin, Liang Xie, Linfang Wang, Weiguo Qing, Longxian Jiao, W. Su, Q. Wang (2015)
Volitinib, a potent and highly selective c‐Met inhibitor, effectively blocks c‐Met signaling and growth in c‐MET amplified gastric cancer patient‐derived tumor xenograft modelsMolecular Oncology, 9
A. Dennis, L. Wang, X. Wan, E. Ficker (2007)
hERG channel trafficking: novel targets in drug-induced long QT syndrome.Biochemical Society transactions, 35 Pt 5
K. Thornton, Geoffrey Kim, V. Maher, Somesh Chattopadhyay, Shenghui Tang, Y. Moon, P. Song, Anshu Marathe, S. Balakrishnan, Hao Zhu, C. Garnett, Qi Liu, B. Booth, Brenda Gehrke, R. Dorsam, Leigh Verbois, Debasis Ghosh, W. Wilson, J. Duan, H. Sarker, S. Miksinski, L. Skarupa, A. Ibrahim, R. Justice, A. Murgo, R. Pazdur (2012)
Vandetanib for the Treatment of Symptomatic or Progressive Medullary Thyroid Cancer in Patients with Unresectable Locally Advanced or Metastatic Disease: U.S. Food and Drug Administration Drug Approval SummaryClinical Cancer Research, 18
Jiyun Yang, J. Fang, Y. Shu, Jian-hua Chang, Gongyan Chen, Jing He, Wei Li, X. Liu, N. Yang, C. Zhou, Jin Huang, Ling Yang, Amir Handzel, M. Frigault, G. Ahmed, C. Egile, S. Morgan, Yi-long Wu (2017)
OA 09.06 A Phase Ib Trial of Savolitinib plus Gefitinib for Chinese Patients with EGFR-Mutant MET-Amplified Advanced NSCLCJournal of Thoracic Oncology, 12
Hong Jia, G. Dai, J. Weng, Zhulin Zhang, Qing Wang, Fengmin Zhou, Longxian Jiao, Yumin Cui, Yongxin Ren, S. Fan, Jinghong Zhou, Weiguo Qing, Yi Gu, Jian Wang, Y. Sai, W. Su (2014)
Discovery of (S)-1-(1-(Imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine (volitinib) as a highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitor in clinical development for treatment of cancer.Journal of medicinal chemistry, 57 18
(2005)
ICH E14 guideline topic E14: the clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for nonantiarrhythmic drugs
R. Shah, J. Morganroth (2015)
Update on Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on QT Interval, Left Ventricular Dysfunction and Overall Risk/BenefitDrug Safety, 38
S Lu (2019)
CT031Cancer Res, 79
A. Dosne, M. Bergstrand, M. Karlsson (2017)
An automated sampling importance resampling procedure for estimating parameter uncertaintyJournal of Pharmacokinetics and Pharmacodynamics, 44
Tarjinder Sahota, C. Dota, T. Vik, Weili Yan, R. Verheijen, Stephen Walker, Yan Li, R. Goldwater, D. Ghiorghiu, A. Mellemgaard, G. Ahmed (2021)
A Randomized, Double‐Blind, Placebo‐ and Positive‐Controlled, Three‐Way Crossover Study in Healthy Participants to Investigate the Effect of Savolitinib on the QTc IntervalClinical Pharmacology in Drug Development, 10
M. Sanguinetti, M. Tristani-Firouzi (2006)
hERG potassium channels and cardiac arrhythmiaNature, 440
Ingo Staudacher, P. Schweizer, H. Katus, Dierk Thomas (2010)
hERG: protein trafficking and potential for therapy and drug side effects.Current opinion in drug discovery & development, 13 1
L. Friberg, G. Isbister, S. Duffull (2006)
Pharmacokinetic-pharmacodynamic modelling of QT interval prolongation following citalopram overdoses.British journal of clinical pharmacology, 61 2
R. Shah, J. Morganroth, D. Shah (2013)
Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on Cardiac Repolarisation (QT Interval)Drug Safety, 36
T. Choueiri, E. Plimack, H. Arkenau, E. Jonasch, D. Heng, T. Powles, M. Frigault, E. Clark, Amir Handzel, H. Gardner, S. Morgan, L. Albiges, S. Pal (2017)
Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 35 26
Rhiannon Jones, Sehyun Oh, Julia Grimstead, Jacob Zimbric, L. Roger, N. Heppel, K. Ashelford, K. Liddiard, E. Hendrickson, D. Baird (2014)
Escape from telomere-driven crisis is DNA ligase III dependent.Cell reports, 8 4
G. Oxnard, M. Cantarini, P. Frewer, G. Hawkins, J. Peters, P. Howarth, G. Ahmed, Tarjinder Sahota, R. Hartmaier, X. Li-Sucholeiki, M. Ahn (2019)
SAVANNAH: A Phase II trial of osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET-driven (MET+), locally advanced or metastatic non-small cell lung cancer (NSCLC), following disease progression on osimertinib.Journal of Clinical Oncology
M. Ahn, Ji-Youn Han, L. Sequist, B. Cho, J. Lee, Sang-We Kim, W. Su, C. Tsai, J.C. Yang, H. Yu, L. Horn, Kang-Yun Lee, V. Haddad, M. Frigault, G. Ahmed, Ling Yang, D. Ghiorghiu, G. Oxnard (2017)
OA 09.03 TATTON Ph Ib Expansion Cohort: Osimertinib plus Savolitinib for Pts with EGFR-Mutant MET-Amplified NSCLC after Progression on Prior EGFR-TKIJournal of Thoracic Oncology, 12
Ryan Henry, E. Barry, Lillian Castriotta, B. Ladd, A. Markovets, Garry Beran, Yongxin Ren, Fengmin Zhou, Ammar Adam, M. Zinda, C. Reimer, Weiguo Qing, W. Su, E. Clark, C. D’Cruz, A. Schuller (2016)
Acquired savolitinib resistance in non-small cell lung cancer arises via multiple mechanisms that converge on MET-independent mTOR and MYC activationOncotarget, 7
L. Sequist, Ji-Youn Han, M. Ahn, B. Cho, H. Yu, Sang-We Kim, J. Yang, J. Lee, W. Su, D. Kowalski, S. Orlov, M. Cantarini, R. Verheijen, A. Mellemgaard, L. Ottesen, P. Frewer, X. Ou, G. Oxnard (2020)
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.The Lancet. Oncology
A. Schuller, E. Barry, Rhys Jones, Ryan Henry, M. Frigault, Garry Beran, David Linsenmayer, M. Hattersley, Aaron Smith, Joanne Wilson, S. Cairo, O. Deas, D. Nicolle, Ammar Adam, M. Zinda, C. Reimer, S. Fawell, E. Clark, C. D’Cruz (2015)
The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient–Derived Xenograft ModelsClinical Cancer Research, 21
Y. Kuryshev, E. Ficker, Lu Wang, Peter Hawryluk, A. Dennis, B. Wible, A. Brown, Jiesheng Kang, Xiao‐Liang Chen, Kaoru Sawamura, William Reynolds, D. Rampe (2005)
Pentamidine-Induced Long QT Syndrome and Block of hERG TraffickingJournal of Pharmacology and Experimental Therapeutics, 312
H. Gan, M. Millward, Y. Hua, Chuang Qi, Y. Sai, W. Su, Jian Wang, Lilin Zhang, M. Frigault, S. Morgan, Liu Yang, J. Lickliter (2019)
First-in-Human Phase I Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Antitumor ActivityClinical Cancer Research, 25
Sen Han, J. Fang, Shun Lu, Linfang Wang, Jing Li, M. Cheng, Yongxin Ren, W. Su (2019)
Response and acquired resistance to savolitinib in a patient with pulmonary sarcomatoid carcinoma harboring MET exon 14 skipping mutation: a case reportOncoTargets and therapy, 12
D. Kazandjian, G. Blumenthal, Huanyu Chen, Kun He, Mona Patel, R. Justice, P. Keegan, R. Pazdur (2014)
FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements.The oncologist, 19 10
Savolitinib is an oral, potent, and highly selective MET-tyrosine kinase inhibitor under investigation in various tumor types. A thorough QT study evaluated effects on QT interval after a 600-mg single savolitinib dose in healthy subjects. We report exposure-response (E-R) modeling from this study to characterize the effects of savolitinib and its metabolites, M2 and M3, on QTc changes. In a novel application, in vitro potencies against hERG current provided mechanistic support to model the metabolites’ effects. The hERG IC50 estimates (95% CI) were 25.8 (22.2–29.9) and 22.6 (14.7–34.6) μM for parent and M2, respectively. The E-R was described by both linear and Emax models, with exposure captured by an active moiety that consisted of savolitinib and M2 concentrations, weighted by the hERG IC50 ratio (1.14). The maximal increase in ΔΔQTcF and EC50 estimates (95% CI) was 18.5 (9.2–27.7) ms and 5709 (2889–8529) nM, respectively. Ignoring M2 contribution resulted in under prediction of QTcF prolongation in the hypothetical case of inhibited M2 clearance; at 300 mg Cmax, the mean (90% CI) of ∆∆QTcF was 9.0 (5.7–12.6) and 5.9 (2.9–8.9) ms using the hERG-informed and parent-only linear models, respectively. Simulations in normal setting confirmed modest QTcF prolongation with 600 mg, but not 300 mg. Using the linear model, the mean (90% CI) maximum ΔΔQTcF were 12.3 (8.6–16.2) and 5.5 (2.6–8.5) ms for 600 and 300 mg, respectively. Further clinical studies will monitor cardiac safety to assess the clinical significance of QT-interval prolongation with savolitinib.
"The AAPS Journal" – Springer Journals
Published: Mar 17, 2021
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.